Analysis true biological signatures without altering, stressing, or damaging cells
LevitasBio Completes Series C Financing of $35 million
05-Dec-2022 -
LevitasBio, Inc. announced it has completed Series C round financing of $35 million to advance its mission of providing powerful, industry-leading methods of cellular analysis.
The funding allows LevitasBio to accelerate its commercial success through the development of next generation ...
cell analysis
Series C financing